~ Trade alerts discuss changes to Tailwinds’ managed portfolios. They are available for premium subscribers only. The information contained here is not meant to be shared, especially with Company managements. Thank you. ~
I have made a number of trades over the last two days in the market. The genesis of the trades is a combination of the overall market, where the volatility has been incredible, along with some fundamental drivers.
To start with, I have sold Amryt (AMYT). The three-month delay in the PDUFA for Oleogel will weigh on this for a while. I like the stock longer term and think it’s a bargain at this valuation, but will likely remain a bargain until after the PDUFA date.
Meanwhile, several of our stocks have been hit harder than Amryt recently and I’m a big believer that biotech is going to bounce very hard, very soon. Therefore, I have taken a lot of the funds from Amryt and put them into TFF Pharma (TFFP), Anixa (ANIX) and INmune (INMB), adding to my positions in three.
Furthermore, I have been trimming Lantern (LTRN) as another source of cash. Why Lantern when it has been hit very hard? It’s early stage and I don’t see any of the catalysts here being as big as the catalysts coming for TFF and INmune. I believe the biggest bounces will come in names with big events.
In particular, I believe Glenn gets deals done soon for TFF, Anixa will show positive biomarker data in January along with starting CAR-T in December, and I believe that INmune’s cancer patients treated with INKmune will show very positive data in December. All of these catalysts should reverse those stocks.
I also continued adding to my new position in Spectra7 (SPVNF), a company I started buying a few days ago. My due diligence continues to come back very positive and I’m likely to keep adding over time.TW Research's Disclaimers & Disclosures: TW Research may have been compensated for writing this article. For a full list of disclaimers and disclosures, please visit http://